



# Nexsphere™

Embolic Gelatin Microspheres

**Resorbable Microspheres.  
Tailored Embolization.**




Nexsphere™ is a gelatin based hydrophilic material for endovascular embolization that is used together with a contrasting agent during vascular embolization for therapeutic and treatment purposes. It is injected into the blood vessel through a microcatheter in order to temporarily occlude the blood vessel. Nexsphere™ is a resorbable microsphere that exhibits embolic performance in a variety of indications with uniform spherical particles, high elasticity and strong cohesion.


## | Indication




Liver cancer



Uterine fibroids




Prostatic hyperplasia




Arterial bleeding

## | Features




### Resorbable microspheres

Temporary embolization microspheres composed of gelatin



### Optimal performance

High elasticity and strong cohesion<sup>1)</sup>




### Patented vial design

Vial designed for contamination prevention  
(Korean design patent No : 3009879200000)


# | Tailored to various indications

Resorbable within 24 hours, applicable to various indications<sup>2)</sup> (Nexsphere-H<sup>®</sup>)

## Histology of Rat Liver<sup>3)</sup>



Embolization




Few hours after embolization


← Non-Resorbable product

← Resorbable product


## Angiography of Porcine Kidney<sup>3)</sup>



Pre-embolization



Embolization



Recanalization few hours after embolization

# | Preclinical study

## Porcine kidney embolization<sup>3)</sup>

### Angiography



Before embolization




1 week after embolization



4 weeks after embolization


### CT scan



Before embolization



1 week after embolization



4 weeks after embolization

1) In-house elasticity and cohesion tests were performed on monolayers of microspheres with a texture analyzer.

2) In-house *in-vitro* degradation test showed that Nexpowder-H was degraded in 37°C of warm saline within 24 hours.

3) Animal studies were conducted by external non-clinical CRO in Korea. Animal study results may or may not be indicative of clinical outcomes in humans.

## | Instructions for use



1

Inject the saline into Nexsphere™ vial using luer lock syringe and shake to disperse and hydrate microspheres



2

Inject the contrast medium into Nexsphere™ vial with saline using luer lock syringe and shake for minutes to mix the contents



3






Transfer the mixed contents to a syringe



4

Inject the mixed Nexsphere™ contents into the lesion via a standard catheter

## | Product Specification

Ordering code	Size(μm)	Weight(mg)	Applicable Catheter Size			
			Outside Diameter		Inside Diameter	
			Fr	mm	Inch	mm
UIGB 100	100-300 	300	1.7	0.60	0.017	0.43
UIGB 300	300-500 	300	1.7	0.60	0.017	0.43
UIGB 500	500-700 	300	1.9	0.64	0.019	0.48
UIGB 700	700-900 	300	2.8	0.93	0.027	0.70
Nexsphere-H	100-300 	250	1.7	0.60	0.017	0.43



NEXTBIO MEDICAL CO., LTD.

6, Venture-ro 100beon-gil, Yeongu-gu, Incheon, Korea 22013

T. +82-32-454-4822 F. +82-32-454-4830 E. sales@nextbiomedical.co.kr

www.nextbiomedical.co.kr

